PO.CTP01.03 · 进行中的临床试验
Phase II and Phase III Clinical Trials in Progress
- CT206 CT206 Larotrectinib（L）治疗NTRK1/2/3扩增（amp）实体瘤患者（pts）：靶向药物与分析利用注册研究（TAPUR）的结果 Larotrectinib (L) in patients (pts) with solid tumors with NTRK1/2/3 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study Jordi Rodon, Michael Rothe, Elizabeth Garrett-Mayer, Nithin Rohatgi, Alvaro G. Menendez, Leighton A. Elliott, Andrew Gregory, Abigail Gregory, Dominique C. Hinshaw, Gina N. Grantham, Susan Halabi, Richard L. Schilsky
- CT207 CT207 一项关于过去五年内有癌症病史患者肝移植结局的前瞻性观察性注册研究：评估肝移植资格 A prospective observational registry study on transplantation of liver outcomes in patients with a history of cancer within the past five years: Evaluating eligibility for liver transplantation Young Kwang Chae, Ronald Seungjune S. Min, Liam Il-Young Chung, Lane Herbert, Jacob Liskh, Sanghwa Kim, Donghoon Shin, Hangyul Lee, Christopher Moore, Sheila Eswaran, Dempsey Hughes, Justin Boike, Amanda Cheung, Daniel Ganger, James Crismale, Taehoon Lee, Laura M. Kulik, Sarang Thaker, Tarik Demir, Andres Duarte-Rojo
- CT208 CT208 一项评估VT-1953局部凝胶治疗恶臭恶性蕈样伤口患者安全性和疗效的2期试验最终结果 Final results from a phase 2 trial testing safety and efficacy of VT-1953 topical gel in patients with malodorous malignant fungating wound Arshit Narang, Prashant Prakash Lad, Shiladitya Sengupta
- CT209 CT209 DiscovHER PAN-206：一项在既往接受过治疗的人表皮生长因子受体2过表达实体瘤患者中开展的zanidatamab 2期泛肿瘤研究 DiscovHER PAN-206: Phase 2 tumor-agnostic study of zanidatamab in patients with previously treated human epidermal growth factor receptor 2-overexpressing solid tumors Vivek Subbiah, Vicky Makker, Do-Youn Oh, Elizabeth Gardener, Elaina Gartner, Funda Meric-Bernstam
- CT210 CT210 消防员职业性癌症筛查：一项全身筛查方式的先导性随机研究 Occupational cancer screening in firefighters: A pilot randomized study of whole-body screening modalities Bryan Bassig, Jennifer Lund, John F. Deeken, Salman Baig, Blair Allais, Rita Stanislawski, Megan Slocum, Elizabeth Hatcher, Jennifer Truax, Inger Rosner, Rebecca Kaltman
- CT211 CT211 Palbociclib（P）治疗CCND1扩增（amp）肺癌（LC）患者（pts）：靶向药物与分析利用注册研究（TAPUR）的结果 Palbociclib (P) in patients (pts) with lung cancer (LC) with CCND1 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study Evan Pisick, Michael Rothe, Elizabeth Garrett-Mayer, Christopher M. Reynolds, Bamidele Adesunloye, Ramya Thota, Kathryn F. Mileham, Kelly Lynch, Rachel E. Sanborn, Timothy L. Cannon, Justin T. Moyers, Janet Tu, Mehmet Akce, Abigail Gregory, Dominique C. Hinshaw, Gina N. Grantham, Susan Halabi, Richard L. Schilsky
-
- CT213 CT213 一项评估EP0031（lunbotinib，新一代选择性RET抑制剂）作为单药及联合化疗治疗晚期RET融合阳性NSCLC患者的I/II期研究 A phase I/II study to evaluate EP0031 (lunbotinib), a next-generation selective RET inhibitor, as monotherapy and in combination with chemotherapy, in patients with advanced RET -fusion-positive NSCLC Jaime Rubio-Perez, Elena Garralda, Benjamin Besse, Mihaela Aldea, Yasir Elamin, Pilar Garrido, Saad Khan, Judy Wang, Luis Paz Ares, Daniel Morgensztern, Philippe Cassier, Salmon Punekar, Stephen V Liu, Matthew H Taylor, Liz Joseph, Andrew G Gianoukakis, Jacobi Hines, Javier Garcia-Corbacho, Pascale Tomasini, David Spigel, Matthew G Krebs, Antoine Italiano, Mohammad Al Masri, Geoff Fisher, Sonia Serrano, Hendrik-Tobias Arkenau, Alex Drilon
- CT214 CT214 DREAM：针对肺局限性恶性肿瘤的双肺移植登记研究——一项针对医学难治性癌症的前瞻性登记研究 DREAM: Double lung transplant REgistry Aimed for lung-limited Malignancies - A prospective registry study for medically refractory cancers Young Kwang Chae, Liam Il-Young Chung, Ronald Seungjune S. Min, Sanghwa Kim, Chan Mi Jung, Yuchan Kim, Brooke Sanson, Rose Dwyer, Tarik Demir, Chitaru Kurihara, Ambalavanan Arunachalam, Ankit Bharat
-
- CT216 CT216 OrigAMI-3：一项在复发、不可切除或转移性RAS/BRAF野生型结直肠癌参与者中比较amivantamab联合FOLFIRI与cetuximab或bevacizumab联合FOLFIRI的随机3期研究 OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic RAS / BRAF wild-type colorectal cancer J. Randolph Hecht, Elena Élez, Cathy Eng, Peter Gibbs, Jenny Seligmann, Ruihua Xu, Kensei Yamaguchi, Jaw Yuan Wang, Hao Wei Teng, Leonardo Trani, Honeylet Wortman-Vayn, Zhengyu Jiang, Brooke Diorio, Patricia Lorenzini, Christine Baudelet, Seema Sethi, Mahadi Baig, Chiara Cremolini
- CT217 CT217 OrigAMI-2：一项在左侧RAS/BRAF野生型转移性结直肠癌中比较amivantamab与cetuximab（两者均联合FOLFOX或FOLFIRI）作为一线治疗的随机3期研究 OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided RAS / BRAF wild-type metastatic colorectal cancer Dirk Arnold, Andres Cervantes, Michel Ducreux, Sae-won Han, Heinz-Josef Lenz, Kei Muro, Kanwal Raghav, Lin Shen, Jaw Yuan Wang, Pei Jye Voon, Hung-Chuh Hsu, Bing Xia, Ryota Iwasawa, Shamita Carrigan, Brooke Diorio, Patricia Lorenzini, Sandip Acharya, Seema Sethi, Mahadi Baig, Filippo Pietrantonio
- CT218 CT218 一项arfolitixorin联合5-氟尿嘧啶（5FU）、奥沙利铂和bevacizumab作为转移性结直肠癌（mCRC）一线治疗的1b/2期研究 Phase 1b/2 study of arfolitixorin in combination with 5-fluorouracil (5FU), oxaliplatin, and bevacizumab as first-line therapy for metastatic colorectal cancer (mCRC) Sebastian Stintzing, Arndt Stahler, Annabel Alig, Isabel Löwstedt, Marcus Thuresson, Roger Tell
- CT219 CT219 一项在接受化疗的新诊断转移性结直肠癌患者中评估mifomelatide（TCMCB07）的随机、双盲、安慰剂对照2期研究：Paradox试验 A randomized, double-blind, placebo-controlled Phase 2 study of mifomelatide (TCMCB07) in patients with newly diagnosed metastatic colorectal cancer undergoing chemotherapy: The Paradox Trial Michael B. Sawyer, Barry A. Badeau, Allison J. Gardner, Meghan Joly, William Riedl, LuAnn Sabounjian, Jillian L. Seiler, Brad Studnitzer, Emma Zhang, Russell Potterfield, Daniel L. Marks
- CT220 CT220 一项1b/2a期研究，评估BXQ-350联合mFOLFOX7和贝伐珠单抗在新诊断转移性结直肠癌（mCRC）患者中的疗效和安全性：中期疗效亚组分析 A Phase 1b/2a study to evaluate the efficacy and safety of BXQ-350 in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma patients (mCRC): Interim efficacy subset analyses Daniel Flora, Ari Baron, Reema Patel, Davendra Sohal, Saima Sharif, Fa Chyi Lee, Julie Anne Gemmill, Gilles H. Tapolsky, James Beach, Michael Gazda, Tariq Arshad
- CT221 CT221 一项关于ENPP1抑制剂vizenpistat联合botensilimab和balstilimab在难治性转移性微卫星稳定型结直肠癌受试者中的1b/2期研究进展报告 A progress report for a Phase 1b/2 study of ENPP1 inhibitor, vizenpistat in combination with botensilimab and balstilimab in subjects with refractory metastatic microsatellite stable colorectal cancer Alexis S. Larsen, Mohan R. Kaadige, Trason Thode, Margaux Steinbach, Scott Houston, Jonathan Northrup, Sunil Sharma
- CT222 CT222 Obrixtamig（BI 764532）用于复发/难治性delta样配体3（DLL3）高表达的肺外神经内分泌癌（epNEC）患者：II期DAREON-5试验剂量扩展部分的进行中试验 Obrixtamig (BI 764532) in patients with relapsed/refractory delta-like ligand 3 (DLL3) high-expressing extrapulmonary neuroendocrine carcinoma (epNEC): trial in progress of the dose expansion part of the Phase II DAREON-5 trial Marianne Pavel, Chris Verslype, Pedro Rocha, Alastair Greystoke, Aman Chauhan, Julia Koevi, Martha Mueller, Eric Song, Valeria Lifke, Andrea Standring, Emily Bergsland
-
- CT224 CT224 EIK1001（一种TLR7/8双重激动剂）联合帕博利珠单抗作为晚期黑色素瘤参与者一线治疗的自适应2/3期研究（Teluride-006） Adaptive phase 2/3 study of EIK1001, a TLR7/8 dual agonist, in combination with pembrolizumab, as first-line therapy in participants with advanced melanoma (Teluride-006) Diwakar Davar, Bernardo Rapoport, Jan C. Simon, Oliver Bechter, Stephane Dalle, Yin Wu, Daniel Brungs, Anna Maria Di Giacomo, Hanna Eriksson, Peter Mohr, Rossanna Pezo, Egle Ramelyte, Gareth Rivalland, Toshifumi Hoki, Geetha Krishna Kaza, Yayan Zhang, Etah Kurland, Alexander Eggermont
- CT225 CT225 ELEGANT：在一项全球性、多中心、随机、开放标签的3期研究中，比较依拉司群（elacestrant）与标准内分泌治疗（ET）在具有高复发风险的淋巴结阳性、雌激素受体阳性（ER+）、HER2阴性（HER2-）早期乳腺癌（eBC）女性和男性患者中的疗效 ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study Aditya Bardia, Virginia Kaklamani, Joyce O’Shaughnessy, Peter Schmid, J. Thaddeus Beck, Michelino De Laurentiis, Giuseppe Curigliano, Hope S. Rugo, Carlos H. Barcenas, William J. Gradishar, Michail Ignatiadis, David A. Cameron, Giulia Tonini, Simona Scartoni, Jennifer Crozier, Tomer Wasserman, Sara M. Tolaney
- CT226 CT226 ADELA：一项双盲、安慰剂对照、随机3期试验，比较依拉司群（Ela）+依维莫司（EVE）对比依拉司群+安慰剂在ESR1突变肿瘤、内分泌治疗（ET）+CDK4/6i进展的ER+/HER2- 晚期乳腺癌（aBC）患者中的疗效 ADELA: A double-blind, placebo-controlled, randomized phase 3 trial of elacestrant (Ela) + everolimus (EVE) versus elacestrant + placebo in ER+/HER2- advanced breast cancer (aBC) patients with ESR1 -mutated tumors progressing on endocrine therapy (ET) + CDK4/6i Antonio Llombart-Cussac, José Manuel Pérez-García, Elena Lopez-Miranda, Cristina Saavedra, Vicente Carañana, Isabel Blancas, Carmen Hinojo-González, Alfonso Cortes-Salgado, Elena Galve, Rui Rui Zhang, Miguel Sampayo-Cordero, Daniel Alcalá-López, Juliana Carvalho-Santos, Olga Boix, Ana Garrido, Carlos H. Barrios, Giuseppe Curigliano, Rupert Bartsch, Anne Claire Hardy Bessard, Tomer Wasserman, Javier Cortés
- CT227 CT227 一项III期研究，评估GLSI-100（GP2 + GM-CSF）在新辅助和术后辅助抗HER2治疗后存在残留疾病或高危PCR的乳腺癌患者中的疗效和安全性，Flamingo-01 Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01 Jaye Thompson, Snehal Patel, Mira Patel, Anu Tammareddi, F. Joseph Daugherty, Mothaffar F. Rimawi
